<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2183-6914</journal-id>
<journal-title><![CDATA[Revista Onconews]]></journal-title>
<abbrev-journal-title><![CDATA[Revista Onconews]]></abbrev-journal-title>
<issn>2183-6914</issn>
<publisher>
<publisher-name><![CDATA[Associação de Enfermagem Oncológica Portuguesa (AEOP)]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2183-69142021000100038</article-id>
<article-id pub-id-type="doi">10.31877/on.2021.42.05</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Reações infusionais: Relatos da experiência de um hospital de dia de oncologia.]]></article-title>
<article-title xml:lang="en"><![CDATA[Infusion Reactions: Experience in Oncology Day Care Unit.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ponte]]></surname>
<given-names><![CDATA[Sandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cabral]]></surname>
<given-names><![CDATA[Carla Santos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cavaco]]></surname>
<given-names><![CDATA[Patrícia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Matos]]></surname>
<given-names><![CDATA[Leonor Vasconcelos de]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernandes]]></surname>
<given-names><![CDATA[Leonor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Hospitalar Lisboa Ocidental Hospital São Francisco Xavier Hospital de Dia de Oncologia Médica]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Hospitalar de Lisboa Ocidental Hospital de São Francisco Xavier Hospital de Dia de Oncologia Médica]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro Hospitalar de Lisboa Ocidental Hospital de São Francisco Xavier Hospital de Dia de Oncologia Médica]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Centro Hospitalar Lisboa Ocidental Hospital São Francisco Xavier Serviço de Oncologia]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>06</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>06</month>
<year>2021</year>
</pub-date>
<numero>42</numero>
<fpage>38</fpage>
<lpage>42</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2183-69142021000100038&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2183-69142021000100038&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2183-69142021000100038&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo A administração de fármacos antineoplásicos pode gerar reações de hipersensibilidade imediatas em Hospital de Dia de Oncologia. A incidência e a gravidade são difíceis de prever e os sinais e sintomas variam, podendo ir de reações cutâneas eritematosas a reações anafiláticas graves, com risco letal. A prevenção é fundamental para reduzir a prevalência e a gravidade destes eventos e o reconhecimento precoce é um elemento chave na resolução do quadro. Definimos como objetivos do presente estudo: revisão das reações infusionais na nossa instituição, particularmente, sua gravidade, incidência, fármacos envolvidos, reações subsequentes, tipo de pré e pós-medicação administradas. Definimos ainda uma sub-análise para identificação de preditores para reações subsequentes. Estudo observacional, retrospetivo e unicêntrico, de análise das notificações de reações infusionais ao longo de três anos. Foram colhidos dados demográficos e relativos à situação de reacção infusional. A análise dos dados foi realizada por meio de estatística descritiva, teste t, teste exato de Fisher e regressão logística, usando o software StataIC 15.1 (StataCorp LLC). A revisão da história patológica e alérgica do doente, a monitorização da adesão medicamentosa da pré-medicação, a reconciliação terapêutica e vigilância de sinais vitais são essenciais na avaliação inicial pré-infusional aos tratamentos antineoplásicos. No nosso estudo, a prevalência de reações infusionais aos taxanos e platinas está alinhada com relatos anteriores da literatura. Revisões institucionais sobre eventos adversos são cruciais para melhorar as práticas atuais e desenvolver protocolos de atuação mais eficientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The administration of antineoplastic drugs can generate immediately hypersensitivity reactions, in Oncology-Day Care Unit hospitals. The incidence and severity are difficult to predict and the signs and symptoms vary, ranging from erythematous skin reactions to severe anaphylactic reactions, with a lethal risk. Prevention is essential to reduce the prevalence and severity of these events and early recognition is a key element in resolving the condition. The objectives of the present study were: reviewing of infusion reactions in our institution, particularly, their severity, incidence, drug, subsequent reactions, type of pre- and post-medication administered. We also defined a sub-analysis to identify predictors for subsequent reactions. Observational, retrospective and single-center study, analyzing the reports of infusion reactions over 3 years. Demographic data and information regarding the infusion reaction situation were collected. Data analysis was performed using descriptive statistics, t test, Fisher&#8217;s exact test and logistic regression, using the software StataIC 15.1 (StataCorp LLC). The review of the patient&#8217;s pathological and allergic history, the monitoring compliance to premedication, therapeutic reconciliation and surveillance of vital signs are essential in the initial pre-infusion assessment of antineoplastic treatments. In our study, the prevalence of infusion reactions to taxanes and platinum is in line with previous reports in the literature. Institutional reviews of adverse events are crucial to improve current practices and develop more efficient practices.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Reações infusionais]]></kwd>
<kwd lng="pt"><![CDATA[Fármacos antineoplásicos]]></kwd>
<kwd lng="en"><![CDATA[Infusional reactions]]></kwd>
<kwd lng="en"><![CDATA[Antineoplasic drugs]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>ESMO</collab>
<source><![CDATA[ESMO Handbook Of Oncological Emergencies]]></source>
<year>2016</year>
<edition>2</edition>
<publisher-name><![CDATA[Europeann Society of Medical Ocology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<collab>NCI</collab>
<source><![CDATA[Common Terminology Criteria for Adverse Events (CTCAE)]]></source>
<year>2017</year>
<publisher-name><![CDATA[U.S. Department of Health and Human Services]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<collab>ESMO</collab>
<article-title xml:lang=""><![CDATA[Guidelines Commitee. Management of infusion reactions to systemic anticancer theraphy: ESMO Clinical Practice Guidelines]]></article-title>
<source><![CDATA[Annals of Oncology]]></source>
<year>2017</year>
<volume>28</volume>
<numero>supl. 4</numero>
<issue>supl. 4</issue>
<page-range>100-18</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joaquim]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[Joana]]></given-names>
</name>
<name>
<surname><![CDATA[Cadinha]]></surname>
<given-names><![CDATA[Susana]]></given-names>
</name>
</person-group>
<source><![CDATA[Reações de Hipersensibilidade em Oncologia]]></source>
<year>2017</year>
<edition>2</edition>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Polyzos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tsavaris]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kosmas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypersensitivity reactions to carboplatin ad-ministration are common but not always severe: A 10-year experience]]></article-title>
<source><![CDATA[Oncology]]></source>
<year>2001</year>
<volume>61</volume>
<page-range>129-33</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gowda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Goel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Berdzik]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypersensitivity reactions to oxaliplatin:Incidence and management]]></article-title>
<source><![CDATA[Oncology (Willistion Park)]]></source>
<year>2004</year>
<volume>18</volume>
<page-range>1671-5</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brandi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pantaleo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Galli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypersensitivity reactions related to oxaliplatin (OHP)]]></article-title>
<source><![CDATA[British Journal of Cancer]]></source>
<year>2003</year>
<volume>89</volume>
<page-range>477-81</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muallaoglu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Disel]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Mertsoylu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Besen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute infusion reactions to chemotherapeutic drugs: A single institute experience]]></article-title>
<source><![CDATA[J BUON]]></source>
<year>2013</year>
<volume>18</volume>
<page-range>261-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
